MORPONIDAZOLE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C11H18N4O4
Molecular Weight	270.285
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC=C(N1CC(O)CN2CCOCC2)[N+]([O-])=O

InChI

InChIKey=GAZGHCHCYRSPIV-UHFFFAOYSA-N

InChI=1S/C11H18N4O4/c1-9-12-6-11(15(17)18)14(9)8-10(16)7-13-2-4-19-5-3-13/h6,10,16H,2-5,7-8H2,1H3

HIDE SMILES / InChI

Molecular Formula	C11H18N4O4
Molecular Weight	270.285
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22184458
Curator's Comment: description was created based on several sources, including: DOI: 10.5897/AJPP12.1353 | https://www.ncbi.nlm.nih.gov/pubmed/25070100 | https://newdrugapprovals.org/2015/08/11/morinidazole/ | https://www.ncbi.nlm.nih.gov/pubmed/24858695

Morinidazole is a novel third generation 5-nitroimidazole-class antimicrobial agent indicated for the treatment of anaerobic bacterial infections including appendicitis and pelvic inflammatory disease. Morinidazole is administered as a racemate. Morinidazole was approved by China Food and Drug Administration (CFDA) on February, 2014. The bactericidal activity of morinidazole, depends on the formation of a redox intermediate metabolite in the bacterium that causes DNA strand breakage, inhibits repair, and, ultimately leads to cell death. The main adverse effects (all are mild) relate to the drug are dizziness, drowsiness and nausea. Recent in vitro assays have demonstrated that higher antiparasitic potency is observed in S- morinidazole than in R-morinidazole.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
UDP-glucuronosyltransferase 1-9 11 Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25070100	Substrate 661
cell death in response to oxidative stress 1 Target ID: GO:0036473 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22184458	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Appendicitis 1 Sources: https://www.pharmacodia.com/web/drug/1_477.html	Primary	Approved 8583	迈灵达® (Mindlinga®) Approved Use Morinidazole is a nitroimidazoles antibiotic indicated for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria. Launch Date 2014
Pelvic inflammatory disease 12 Sources: https://www.pharmacodia.com/web/drug/1_477.html	Curative	Approved 8583	迈灵达® (Mindlinga®) Approved Use Morinidazole is a nitroimidazoles antibiotic indicated for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria. Launch Date 2014
Periodontal diseases 4 Sources: DOI: 10.5897/AJPP12.1353	Curative	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
12514.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32152080/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
76830.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32152080/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
60.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
89.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.94 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32152080/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MORINIDAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
72.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24820074/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		MORINIDAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg single, intravenous Studied dose Dose: 500 mg Route: intravenous Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/	Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/
500 mg single, intravenous Studied dose Dose: 500 mg Route: intravenous Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/	Sources: https://pubmed.ncbi.nlm.nih.gov/24290410/

PubMed

Title	Date	PubMed
Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment.	2014-02	24290410
Simultaneous determination of morinidazole and its carbonylation metabolite in human plasma: application to a pharmacokinetic study involving renal insufficiency patients and healthy volunteers.	2013-03-25	23298909
Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9.	2012-03	22184458

Patents

Sample Use Guides

In Vivo Use Guide

500 mg (100 mL injection) twice daily every 6-8 hours continuously for 5-7 days

Route of Administration: Intravenous

In Vitro Use Guide

Minimum inhibitory concentration (MIC) of Morinidazole to several anaerobic bacteria: Peptostreptococcus anaerobius (0.25 mg/l); Veillonella parvula (0.31 mg/l); Actinomyces dentocariosus (0.25 mg/l); Porphyromonas gingivalis (2.0 mg/l); Bacteroides thetaiotaomicron (4.0); Prevotella melaninogenica (0.5 mg/l).

Substance Class	Chemical Created by `admin` on `Tue Apr 01 20:50:47 GMT 2025` Edited by `admin` on `Tue Apr 01 20:50:47 GMT 2025`
Record UNII	TUPWG40JAL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MORPONIDAZOLE

Official Name

English

MORINIDAZOLE

Preferred Name

English

Morinidazole [WHO-DD]

Common Name

English

(±)-1-(2-METHYL-5-NITRO-1H-IMIDAZOL-1-YL)-3-MORPHOLINOPROPAN-2-OL

Systematic Name

English

morponidazole [INN]

Common Name

English

Code System Code Type Description

FDA UNII

TUPWG40JAL